Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection

被引:28
|
作者
Labarrere, CA
Nelson, DR
Park, JW
机构
[1] Indiana Univ, Riley Hosp, Clarian Hlth Partners, Methodist Res Inst, Indianapolis, IN USA
[2] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA
[3] Dresden Inst Heart & Circulatory Res, Dresden, Germany
关键词
D O I
10.1097/00001573-200103000-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transplant-associated coronary artery disease (CAD) is the principal limiting factor for the long-term survival of heart trans plant patients. This review discusses early risk factors for the subsequent development of transplant-associated CAD. Early risk factors associated with a prothrombogenic microvasculature, such as deposition of microvascular fibrin, depletion of vascular tissue plasminogen activator, presence of endothelial activation of the allograft arterial tree, and loss of vascular antithrombin, as well as changes in circulation (ie, detectable serum cardiac troponin I and elevated serum soluble intercellular adhesion molecule-1 levels) are presented and discussed. New therapies that could improve the status of the allograft microvasculature and may prevent or mitigate the development of transplant-associated CAD are considered. Curr Opin Cardiol 2001, 16:110-117 (C) 2001 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 50 条
  • [21] Treatment of chronic allograft rejection
    Fan Yu
    Xie Tong
    Xu Da
    Wang Xiang-hui
    Jin Wen-hua
    CHINESE MEDICAL JOURNAL, 1993, (07)
  • [22] Pathogenesis of chronic allograft rejection
    Joosten, SA
    van Kooten, C
    Paul, LC
    TRANSPLANT INTERNATIONAL, 2003, 16 (03) : 137 - 145
  • [23] CHRONIC REJECTION OF THE LIVER ALLOGRAFT
    LOWES, JR
    HUBSCHER, SG
    NEUBERGER, JM
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1993, 22 (02) : 401 - 420
  • [24] CHRONIC ALLOGRAFT-REJECTION
    HAYRY, P
    ISONIEMI, H
    YILMAZ, S
    MENNANDER, A
    LEMSTROM, K
    RAISANENSOKOLOWSKI, A
    KOSKINEN, P
    USTINOV, J
    LAUTENSCHLAGER, I
    TASKINEN, E
    KROGERUS, L
    AHO, P
    PAAVONEN, T
    IMMUNOLOGICAL REVIEWS, 1993, 134 : 33 - 81
  • [25] Therapies for Chronic Allograft Rejection
    Kim, Min Young
    Brennan, Daniel C.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Chronic allograft damage index as a surrogate marker for chronic allograft rejection
    Yilmaz, S
    Nutley, M
    Taskinen, E
    Paavonen, T
    Hayry, P
    BIOMARKERS OF DISEASE: AN EVIDENCE-BASED APPROACH, 2002, : 433 - 441
  • [27] The Role of Mast Cells in Acute and Chronic Cardiac Allograft Rejection
    Itoh, S.
    Nakae, S.
    Velotta, J.
    Kosuge, H.
    Schrepter, S.
    Connolly, A.
    Tsai, M.
    Adachi, H.
    Galli, S. J.
    Robbins, R. C.
    Fischbein, M. P.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (02): : S111 - S112
  • [28] Downregulation of Connexin 43 expression in chronic cardiac allograft rejection
    Polavaram, L
    Zaghi, D
    Gui, GG
    Ahluwalia, HS
    Sen, LY
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 176A - 176A
  • [29] New approaches to the management of acute and chronic cardiac allograft rejection
    Isobe, M
    Suzuki, J
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (05): : 315 - 327
  • [30] BIOLOGICAL MARKERS OF ALLOGRAFT-REJECTION
    RONDEAU, E
    NEPHROLOGIE, 1990, 11 (01): : 23 - 28